People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Zymeworks Inc. | — | Biotechnology | Series C | $143.3M | $2.5B | 2009 |
| Presidio Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $72.6M | $742.2M | 2009 |
| Celator Pharmaceuticals Inc | — | Pharmaceuticals | Series B | $63.5M | $1.3B | 2011 |
| Zymeworks Inc. | — | Biotechnology | Series C | $50.0M | $541.0M | 2023 |
| Aquinox Pharmaceuticals (Usa) Inc | — | Pharmaceuticals | Series A | $30.6M | $433.6M | 2013 |
| Profound Medical Corp. | — | Biotechnology | Series A | $877K | $31.7M | 2017 |
Kenneth Galbraith at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Galbraith on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Asish Xavier | 1 | 18 |
| Scott Jackson | 1 | 13 |
| Srinivas Akkaraju | 1 | 10 |
| Richard S. Kollender | 1 | 7 |
| Elaine Jones | 1 | 6 |
| Jeffrey C. Smith | 1 | 5 |
| Daniel Perez | 1 | 5 |
| Robert Williamson | 1 | 5 |
| Felix Baker | 1 | 4 |
| Brenda D Gavin | 1 | 3 |
| J Kevin Buchi | 1 | 3 |
| Ian Ihnatowycz | 1 | 3 |
| Shermaine Tilley | 1 | 3 |
| Noel Hall | 1 | 3 |
| David Tucker | 1 | 3 |
| Arun Menawat | 1 | 3 |
| Scott S. Morenstein | 1 | 3 |
| Amos Michelson | 1 | 2 |
| Daniel Levitt | 1 | 2 |
| Rodney Ferguson | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.